Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) Releases Quarterly Earnings Results, Misses Expectations By $0.10 EPS

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.52) by ($0.10), Zacks reports.

Lakewood-Amedex Biotherapeutics Stock Down 22.3%

Shares of NASDAQ LABT opened at $0.22 on Tuesday. The firm has a 50-day moving average price of $0.96. Lakewood-Amedex Biotherapeutics has a 52-week low of $0.17 and a 52-week high of $98.20.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. Wall Street Zen downgraded shares of Lakewood-Amedex Biotherapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, November 7th. HC Wainwright assumed coverage on shares of Lakewood-Amedex Biotherapeutics in a research report on Wednesday, October 28th. They issued a “buy” rating for the company. Finally, Weiss Ratings raised shares of Lakewood-Amedex Biotherapeutics from a “sell (e-)” rating to a “sell (e)” rating in a research report on Friday, October 2nd. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Lakewood-Amedex Biotherapeutics presently has a consensus rating of “Hold”.

Read Our Latest Analysis on LABT

About Lakewood-Amedex Biotherapeutics

(Get Free Report)

Lakewood-Amedex Biotherapeutics is a biotechnology company focused on developing treatments for bacterial infections, including infections caused by drug-resistant pathogens. Its research centers on bisphosphocins, a class of investigational antimicrobial compounds. The company’s activities are primarily research and development; its investigational compounds should not be confused with approved medicines or commercially available products. Publicly available information about its specific product pipeline, operating geographies and leadership is limited.

Read More

Receive News & Ratings for Lakewood-Amedex Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakewood-Amedex Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.